Quantitative Assessment of Tumor Ablation

Overview

About this study

The purpose of this study is to retrospectively analyze potential correlation between ablation zone/margin and tumor recurrence by using the Software Product to quantitatively evaluate diagnostic/pre-operative CT images, intra-operative CT images during ablation procedures, and follow-up CT images; and to apply and evaluate the FDA cleared Software Product during CT-guided ablation procedures for intra-operative monitoring and confirmation.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Mayo patients who underwent or will undergo ablation procedures.
  • Patients 18 years or older
  • ≤3 lesions amendable to ablation

Exclusion Criteria:

  • Severe renal insufficiancy as defined by eGFR ≤30 (not on dialysis)
  • Severe reaction to contrast not amendable to premedication

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Matthew Callstrom, M.D., Ph.D.

Open for enrollment

Contact information:

Desirae Howe-Clayton

(507) 255-0111

Howe.Desirae@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20306995

Mayo Clinic Footer